Navigation Links
Authors Review Astrodome Medical Response to Hurricane Katrina

ed high blood pressure, respiratory infections, and GI infections. Many evacuees needed treatments to control chronic diseases like diabetes and asthma. Dermatitis and other skin conditions, likely caused by exposure to contaminated floodwaters, were common. Many evacuees had acute emotional problems in need of immediate attention, while others had potentially serious psychiatric conditions. Children and the elderly accounted for a large percentage of evacuees, and posed special requirements to ensure their health and safety.

Among the many obstacles encountered was the lack of a system for identifying and registering evacuees in the overall shelter population. In many cases, patients seen at the clinic couldn't be found for follow-up, such as when important test results came back. Another challenge was confirming the credentials of health care professionals volunteering to help at the clinic—some were retired doctors or nurses with expired licenses, while at least one impostor falsely claimed to be a doctor.

The authors hope their experience—the successes as well as difficulties—will prove useful to other communities in preparing the medical response to future disasters. "With adequate planning and organization, supervision and cooperation, resources and leadership, other communities can respond fully and successfully, as did Houston and Harris County in the aftermath of Katrina," they conclude.

In his editorial, Dr. Nusbaum offers a tough critique of the overall public health response to Katrina, which he characterizes as a "debacle." Areas of weakness played out in succession, including the lack of an effective evacuation plan, the inability to provide aid to those left behind in the storm area, the "ad hoc" evacuation process, and the "continued diaspora" of much of the affected community.

Dr. Nusbaum proposes a fundamentally different approach to preparing for mass evacuations in the future, based on the premise t
'"/>




Page: 1 2 3

Related medicine news :

1. Dr. Scott Hammer Authors Two New Guidelines for HIV Treatment
2. Fast-Multiplying Lawsuits Can Stymie Medical Science, Authors Warn
3. US Reviews Risks Of Tamiflu After 12 Children Die
4. Breast Cancer Examinations To Be Reviewed In Irish Hospitals
5. BioCryst’s Bird Flu Drug Enjoys Fast-Track Review By FD
6. FDA Accords Priority Review For Pediatric Crohns Disease Drug
7. The Lancet Calls For Review Of Regulatory Process Of Drug Trials
8. Review of Pramod Mahajans Injuries
9. Vaticans Council Reviews Condom Usage
10. Review of Reversal of Spread of Diseases in Africa
11. Closure of NHS Borders Hospitals to be Reviewed
Post Your Comments:
Breaking Medicine Technology:RetireSafe Announces Intention to Key Vote Senator Dorgan's Drug Importation Amendment (SA 2793) 2Dynatronics Receives 180-Day NASDAQ Extension 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 3Congressional Health Reform Bill Falls Short on Comprehensive and Affordable Coverage for Low Income Children 61194 1Congressional Health Reform Bill Falls Short on Comprehensive and Affordable Coverage for Low Income Children 61194 2Congressional Health Reform Bill Falls Short on Comprehensive and Affordable Coverage for Low Income Children 61194 3Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization 14801 1Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization 14801 2Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization 14801 3Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization 14801 4Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization 14801 5Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization 14801 6Dynatronics to Release First Quarter Results Friday November 13 2009 3B Conference Call Set for 1 3A30 p m ET 6188 1